Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB — APOLLO

Peripheral Arterial Diseases Clinical Trial

Official title:
A Randomized, International, Multicenter, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Subjects With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

Status Completed

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy and safety of actovegin in participants with peripheral arterial disease (PAD) Fontaine Stage IIB.

Clinical Trial Description

The study will enroll approximately 366 participants. Participants will be randomly assigned to one of the two treatment groups in 1:1 ratio: 1. Actovegin 2. Placebo (dummy inactive substance) - this is a tablet/intravenous infusion that looks like the study drug but has no active ingredient All participants will be asked to take intravenous infusion for 2 weeks followed by oral tablets for 10 weeks. This multi-center trial will be conducted Russia, Georgia, and Kazakhstan. The overall time to participate in this study is 25 to 26 weeks. Participants will make multiple visits to the clinic, and 12 weeks after last dose of study drug for a follow-up assessment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03469349
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 3
Start date	May 1, 2018
Completion date	August 28, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02041169` - Lower Extremity Peripheral Arterial Disease and Exercise Ischemia	N/A
Completed	`NCT01436435` - The Jetstream (JET) Post-market Registry	Phase 4
Completed	`NCT01983449` - Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease	Phase 4
Completed	`NCT00640770` - Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease	Phase 4
Recruiting	`NCT05192707` - Transcutaneous Oxygen Pressure (TcPO2) Determination.
Withdrawn	`NCT02531139` - The Effect of Blood Pressure on Cerebral Perfusion During Vascular Surgery	N/A
Completed	`NCT00652418` - Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography	Phase 2
Completed	`NCT02920125` - Study the Result of Ayurvedic SUVED & Reimmugen (Colostrum) Treatment on Vascular Disease, CAD, CVA, DVT.	Phase 3
Completed	`NCT02273232` - Effects of Remote Ischemic Preconditioning on Moderate PVD Patients A Pilot Randomized Control Trial	Phase 1
Completed	`NCT01952756` - Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)	Phase 4
Completed	`NCT01419418` - Patients' Perspectives of Factors That Support the Management of Peripheral Arterial Disease for Improved Outcomes	N/A
Completed	`NCT02066740` - EverFlex™ Self-expanding Peripheral Stent With Entrust™ Delivery System Clinical Study	N/A
Completed	`NCT01336101` - Evaluation of Efficacy of the EPIC™ Self-Expanding Nitinol Vascular Stent	N/A